ArticleCurrent medicinal chemistry2026
Single-cell RNA Sequencing Identifies Prognostic Biomarkers in Extramedullary Multiple Myeloma.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundMultiple myeloma (MM) is the second most common hematologic malignancy, accounting for approximately 10% of all hematological cases, with higher morbidity and mortality.
objectiveThis study aimed to investigate the clonal evolutionary characteristics to identify novel prognostic biomarkers associated with extramedullary progression in MM.
methodsWe downloaded transcriptomic profiles and single-cell microarray (scRNA-seq) data from public databases. Then, we used the LASSO method to develop a prognostic signature and validated its efficacy using external MM cohorts. We evaluated the differences in the immune microenvironment and drug sensitivity (IC50) between the different risk score groups. scRNA-seq analysis identified key cell types through AUCell scores, cell communication, and differentiation trajectory analyses.
resultsIn total, 126 DEGs were identified as crucial genes associated with extramedullary and intramedullary MM. After LASSO analysis, seven signature genes were selected to develop a risk score model, and high-risk patients showed worse outcomes. Subsequently, the nomogram incorporating age, albumin, b2m, LDH, and RiskScore predicted 1-, 3-, and 5-year outcomes with high AUCs. Immune analyses showed that 25 immune cell types, 35 immune checkpoints, 27 chemokines, 20 MHC molecules, and 14 receptor- related genes differed significantly between the two risk groups. We also identified 116 drugs (roscovitine and JNK inhibitor VIII) with significantly different IC50 values between the two risk groups. CD4+ T cells exhibited the highest signature gene activity. CellChat analysis demonstrated enhanced communication between CD4+, NK, and CD8+ T cells.
conclusionOur study has proposed a risk score model based on seven identified signature genes for MM prognosis and revealed CD4+ T cells to be a major immune cell type associated with MM progression, contributing to personalized treatment decision-making and precise risk stratification of MM.
Indexed as
Identifiers
40326029What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.